Integrin α5β1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors
Open Access
- 15 January 2013
- Vol. 5 (1), 27-47
- https://doi.org/10.3390/cancers5010027
Abstract
Integrins are transmembrane heterodimeric proteins sensing the cell microenvironment and modulating numerous signalling pathways. Changes in integrin expression between normal and tumoral cells support involvement of specific integrins in tumor progression and aggressiveness. This review highlights the current knowledge about α5β1 integrin, also called the fibronectin receptor, in solid tumors. We summarize data showing that α5β1 integrin is a pertinent therapeutic target expressed by tumoral neovessels and tumoral cells. Although mainly evaluated in preclinical models, α5β1 integrin merits interest in particular in colon, breast, ovarian, lung and brain tumors where its overexpression is associated with a poor prognosis for patients. Specific α5β1 integrin antagonists will be listed that may represent new potential therapeutic agents to fight defined subpopulations of particularly aggressive tumors.This publication has 157 references indexed in Scilit:
- The interaction between caveolin-1 and Rho-GTPases promotes metastasis by controlling the expression of alpha5-integrin and the activation of Src, Ras and ErkOncogene, 2011
- Ligand-independent activation of c-Met by fibronectin and α5β1-integrin regulates ovarian cancer invasion and metastasisOncogene, 2010
- Increased potency of the PHSCN dendrimer as an inhibitor of human prostate cancer cell invasion, extravasation, and lung colony formationClinical & Experimental Metastasis, 2010
- IntegrinsCell and tissue research, 2009
- The structure of the integrin αIIbβ3 transmembrane complex explains integrin transmembrane signallingThe EMBO Journal, 2009
- Integrins in angiogenesis and lymphangiogenesisNature Reviews Cancer, 2008
- PTHrP increases transcriptional activity of the integrin subunit α5British Journal of Cancer, 2007
- P-selectin activates integrin-mediated colon carcinoma cell adhesion to fibronectinExperimental Cell Research, 2006
- Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumoursBritish Journal of Cancer, 2006
- Extensive Vasculogenesis, Angiogenesis, and Organogenesis Precede Lethality in Mice Lacking All αv IntegrinsCell, 1998